Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: Implications in anti-leukaemic strategy

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 2039-2052

  Fang, Zhi Hong ^a   Dong, Chun Lan ^a   Chen, Zhong ^a   Zhou, Bin ^b   Liu, Na ^a   Lan, Hai Feng ^a   Liang, Lu ^a   Liao, Wen Bin ^a   Zhang, Lei ^a   Han, Zhong Chao ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

BCR ABL; C Myc; Leukaemia; Signal transduction; Survivin; Transcription

Indexed keywords

BCR ABL PROTEIN; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MYC PROTEIN; PRIMER DNA;

ARTICLE; CHRONIC MYELOID LEUKEMIA; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICROTUBULE-ASSOCIATED PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 72949109124     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00549.x     Document Type: Article

References (52)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007 7 : 441 453.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000 96 : 3343 3356.
3. Fernandez-Luna JL. Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells. Apoptosis. 2000 5 : 315 318.
4. Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000 191 : 977 984.
5. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000 96 : 2269 2276.
6. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005 105 : 3303 3311.
7. Nieborowska-Skorska M, Hoser G, Kossev P, et al. Complementary functions of the antiapoptotic protein A1 and serine/ threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood. 2002 99 : 4531 4539.
8. Mayerhofer M, Florian S, Krauth MT, et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res. 2004 64 : 3148 3154.
9. Yoshida C, Yoshida F, Sears DE, et al. Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood. 2007 109 : 1211 1219.
10. Svensson E, Vidovic K, Lassen C, et al. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells. Leukemia. 2007 21 : 2485 2494.
11. Tipping AJ, Deininger MW, Goldman JM, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol. 2003 31 : 1073 1080.
12. Ravandi F, Kantarjian HM, Talpaz M, et al. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 91 : 1964 1972.
13. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003 3 : 46 54.
14. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008 8 : 61 70.
15. Cong XL, Han ZC. Survivin and leukemia. Int J Hematol. 2004 80 : 232 238.
16. Badran A, Yoshida A, Wano Y, et al. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res. 2003 23 : 589 592.
17. Hernández-Boluda JC, Bellosillo B, Vela MC, et al. Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma. 2005 46 : 717 722.
18. Moriai R, Asanuma K, Kobayashi D, et al. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res. 2001 21 : 595 600.
19. Wang Z, Sampath J, Fukuda S, et al. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 65 : 8224 8232.
20. Carter BZ, Mak DH, Schober WD, et al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006 107 : 1555 1563.
21. Zhou B, Bi YY, Han ZB, et al. G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. J Thromb Haemost. 2006 4 : 993 1002.
22. Cong XL, Li B, Yang RC, et al. Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy. Leukemia. 2005 19 : 1517 1524.
23. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA. 2004 101 : 15100 15105.
24. Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007 109 : 4399 4405.
25. de Groot RP, Raaijmakers JA, Lammers JW, et al. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood. 1999 94 : 1108 1112.
26. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 2002 115 : 575 585.
27. Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004 114 : 1117 1127.
28. Knauer SK, Krämer OH, Knösel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J. 2007 21 : 207 216.
29. Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood. 2004 104 : 495 501.
30. Cosgrave N, Hill AD, Young LS. Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol. 2006 37 : 377 390.
31. Xie S, Lin H, Sun T, et al. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002 21 : 7137 7146.
32. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance Int J Cancer. 2005 114 : 509 512.
33. Peng XH, Karna P, Cao Z, et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006 281 : 25903 25914.
34. Notari M, Neviani P, Santhanam R, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 2006 107 : 2507 2516.
35. Samanta AK, Lin H, Sun T, et al. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006 66 : 6468 6472.
36. Xie S, Wang Y, Liu J, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 2001 20 : 6188 6195.
37. Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003 362 : 205 209.
38. Ma H, Nguyen C, Lee KS, et al. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene. 2005 24 : 3619 3631.
39. Gu L, Chiang KY, Zhu N, et al. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol. 2007 35 : 957 966.
40. Jiang Y, Saavedra HI, Holloway MP, et al. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004 279 : 40511 40520.
41. Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002 277 : 3247 3257.
42. Zhu N, Gu L, Findley HW, et al. KLF5 interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem. 2006 281 : 14711 14718.
43. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999 344 : 305 311.
44. Mayerhofer M, Valent P, Sperr WR, et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002 100 : 3767 3775.
45. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 1999 59 : 3143 3151.
46. Kawakami H, Tomita M, Matsuda T, et al. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer. 2005 115 : 967 974.
47. Levens D. Disentangling the MYC web. Proc Natl Acad Sci USA. 2002 99 : 5757 5759.
48. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992 70 : 901 910.
49. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005 435 : 839 843.
50. Muchmore SW, Chen J, Jakob C, et al. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell. 2000 6 : 173 182.
51. Wang H, Hammoudeh DI, Follis AV, et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther. 2007 6 : 2399 2408.
52. Wang Y, Cai D, Brendel C, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007 109 : 2147 2155.